Ustekinumab Versus Other Biologics in Psoriatic Disease: Which Medications Increase Risk for Infection?
In a recent study, researchers compared ustekinumab versus other biologics and apremilast for risk of serious infection requiring hospitalization among patients with psoriasis (PsO)...
Patient Characteristics at Diagnosis May Predict 10-Year Psoriasis Disease Course
Early identification of certain patient factors may predict long-term outcomes in psoriasis, according to a study.
Between 2001 and 2005, patients were enrolled in the...
Golimumab Treatment Retention Comparison: RA, AxSpA, and PsA
A study retrospectively compared rates of treatment retention with golimumab among patients with rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), and psoriatic arthritis (PsA).
“Retention of...
Tofacitinib Under Review for Heart-related Issues, Cancer in Canada Months after FDA Announcement
Health Canada is conducting a safety review into tofacitinib following reports that the drug may be associated with serious heart-related issues and cancer.
Tofacitinib, manufactured...
Rheum Round-up: Interview with Dr. Keenan, Rixutimab Ups Severe COVID-19 Risk, PsA Drug Comparison
This week in the DocWire News rheumatology section, I interviewed Robert Keenan, MD, an adjunct associate professor at Duke University School of Medicine, Division...
Upadacitinib versus Adalimumab: How Do These Arthritis Drugs Compare?
A higher dose of upadacitinib was superior to adalimumab in patients with psoriatic arthritis, according to a study, but outcomes did not largely differ...
Rheum Round-up: Psoriatic Arthritis Medication Research, Hip Fracture Survival
Guselkumab Safe, Effective in Biologic-naïve Patients with Psoriatic Arthritis
Guselkumab was a safe and effective treatment for biologic-naïve patients with psoriatic arthritis (PsA), according to...
